Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results
Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results Yahoo Finance
Covered in this story
What has happened since
- Merck & Co. is down 0.2% since this was published, 3 days ago.
- Information Services Group Inc is down 1.9% since this was published, 3 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Merck & Co.
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
- Cantor Fitzgerald: $142 → $145 by Oct 2027 · Neutral via MarketBeat
- Morgan Stanley: $143 → $177 by Oct 2027 · Overweight via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 36 stories mentioning Merck & Co., the earliest published 13 Jul 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.